Track market-moving stories before they get noisy

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 7.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 43,198 shares of the company’s stock after selling 3,332 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.05% of IDEXX Laboratories worth $24,392,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Elyxium Wealth LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $3,666,459,000. J. Stern & Co. LLP grew its stake in IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after buying an additional 2,642,200 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of IDEXX Laboratories by 63,503.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after buying an additional 1,442,174 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of IDEXX Laboratories by 318.1% in the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after buying an additional 592,834 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $332,265,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Down 0.6% Shares of NASDAQ:IDXX opened at $563.81 on Tuesday. The stock has a market capitalization of $44.47 billion, a P/E ratio of 41.52, a price-to-earnings-growth ratio of 3.10 and a beta of 1.55. The stock’s 50-day moving average price is $555.13 and its 200-day moving average price is $598.49. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $513.02 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the business posted $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analyst Upgrades and Downgrades IDXX has been the subject of a number of research analyst reports. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Finally, Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

Get Our Latest Report on IDXX

About IDEXX Laboratories (Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

See Also Five stocks we like better than IDEXX Laboratories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Has $23.57 Million Stock Holdings in Vanguard FTSE Europe ETF $VGK

NEXT HEADLINE »La-Z-Boy Incorporated $LZB Shares Acquired by Allspring Global Investments Holdings LLC

Key Takeaways ISRG is expanding AI-enabled robotic surgery with growing da Vinci, Ion and digital platform adoption. IDXX is driving growth through diagnostics, software, international expansion and strong customer retention.ALC is gaining traction from new product launches, Vision Care growth and expanding Unity platform adoption. Over the past several months, generative AI (GenAI) in the medical devices industry has moved from experimental to operational use. Applications include generating synthetic medical images, simulating disease progression, creating potential drug molecules and simulating their effects, to accelerate the long and costly drug development process.

Grand View Research estimates the global AI in the healthcare market to witness a CAGR of 38.9% from 2026 to 2033, building on a $36.67 billion valuation in 2025. Despite these positives, a few medical device giants that extensively use AI tools lagged in the first half of 2026. Their stock prices have provided negative returns during this time. 

However, strong business models of these companies and their current favorable Zacks Rank indicate northward journey of stock prices in the second half. Three such companies are: Intuitive Surgical Inc. (ISRG - Free Report) , IDEXX Laboratories Inc. (IDXX - Free Report) and Alcon Inc. (ALC - Free Report) . Each of our picks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

The chart below shows the price performance of our three picks year to date.

Image Source: Zacks Investment Research

Intuitive Surgical Inc.Intuitive Surgical is increasingly embedding AI and digital tools into its robotic ecosystem. ISRG operates in the robotic surgery market for soft tissue procedures, where adoption is supported by the shift toward minimally invasive care. The company’s platforms include the da Vinci surgical system and the Ion endoluminal system.

ISRG continues to add digital capabilities that can improve training, workflow and program management for hospitals. These efforts include software and analytics that connect systems, instruments and services and can deepen customer engagement over time.

In the first quarter of 2026, ISRG highlighted expanded adoption of its da Vinci, Ion and digital platforms, supporting continued investment in the connected ecosystem. Over time, digital features can differentiate the installed base and support incremental service and software revenues as hospitals focus on standardizing surgical programs.

Intuitive Surgical has an expected revenue and earnings growth rate of 16.5% and 16.7%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 0.1% over the last 30 days. 

IDEXX Laboratories Inc.IDEXX Laboratories’ robust strategic execution is highlighted by new business gains, high customer retention levels and solid net price realization. Continued momentum in CAG Diagnostics’ recurring revenues is supported by improved net price realization. 

IDXX is also advancing its innovation-driven growth strategy, including high-impact menu additions to the Catalyst platform. International expansion remains an attractive opportunity for IDEXX as it continues investing in its commercial footprint in regions where customer readiness and growth potential are strongest. 

IDXX’s software solutions are further supporting growth by improving clinic workflows and encouraging greater utilization of diagnostics. Lower debt levels on the balance sheet are also encouraging.

IDEXX Laboratories has an expected revenue and earnings growth rate of 9.6% and 12.2%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.1% over the last 60 days.

Alcon Inc.Alcon is seeing uptake from new launches across both franchises, with Unity supporting equipment momentum and PanOptix Pro and TruPlus strengthening its IOL lineup. ALC’s Vision Care growth is being led by dry eye, as Tryptyr expands payer coverage and Systane continues to gain share. Newer reusable lenses are helping offset declines in legacy products.

ALC’s growth strategy remains tied to a steady cadence of launches that can expand addressable procedures and support price and mix across both segments. Unity VCS and Unity CS are at the center of the current equipment cycle. 

ALC highlighted continued momentum in the first quarter of 2026 as installations expand and surgeon feedback emphasizes workflow integration. Unity VCS was also named an Edison Award winner in 2026, which provides external validation for the platform.

Alcon has an expected revenue and earnings growth rate of 7.3% and 14%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 0.9% over the last 90 days. 

-

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2026 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year.

The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 922025.

2026 Investor Day

IDEXX Laboratories, Inc. will host its 2026 Investor Day on Thursday, August 13, 2026, at its corporate headquarters in Westbrook, Maine from 8:00 am to approximately 12:00 pm ET. A live webcast of the presentations will be available on www.idexx.com/investors. Advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact [email protected]. Additional information on IDEXX’s Investor Day will be provided closer to the date of the event.

About IDEXX Laboratories, Inc.

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.

More News From IDEXX Laboratories, Inc.

Back to Newsroom

Investors in IDEXX Laboratories, Inc. (IDXX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 17, 2026 $980 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?Clearly, options traders are pricing in a big move for IDEXX Laboratories shares, but what is the fundamental picture for the company? Currently, IDEXX Laboratories is a Zacks Rank #3 (Hold) in the Medical – Instruments industry that ranks in the Bottom 33% of our Zacks Industry Rank. Over the last 60 days, the Zacks Consensus Estimate for the current quarter has moved from $3.94 per share to $3.95 in that period.

Given the way analysts feel about IDEXX Laboratories right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.

We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.

Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.

The Zacks Earnings ESP, ExplainedThe Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.

The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction. The Zacks Rank is also factored into the ESP metric to better help find companies that appear poised to top their next bottom-line consensus estimate, which will hopefully help lift the stock price.

In fact, when we combined a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. Perhaps most importantly, using these parameters has helped produce 28.3% annual returns on average, according to our 10 year backtest.

Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.

Should You Consider Idexx Laboratories?The final step today is to look at a stock that meets our ESP qualifications. Idexx Laboratories (IDXX - Free Report) earns a #3 (Hold) five days from its next quarterly earnings release on May 5, 2026, and its Most Accurate Estimate comes in at $3.45 a share.

By taking the percentage difference between the $3.45 Most Accurate Estimate and the $3.42 Zacks Consensus Estimate, Idexx Laboratories has an Earnings ESP of +0.77%. Investors should also know that IDXX is one of a large group of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

IDXX is one of just a large database of Medical stocks with positive ESPs. Another solid-looking stock is HCA Healthcare (HCA - Free Report) .

HCA Healthcare is a Zacks Rank #3 (Hold) stock, and is getting ready to report earnings on July 24, 2026. HCA's Most Accurate Estimate sits at $7.39 a share 85 days from its next earnings release.

The Zacks Consensus Estimate for HCA Healthcare is $7.38, and when you take the percentage difference between that number and its Most Accurate Estimate, you get the Earnings ESP figure of +0.10%.

IDXX and HCA's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.

Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.

Now that we know how important earnings and earnings surprises are, it's time to show investors how to take advantage of these events to boost their returns by utilizing the Zacks Earnings ESP filter.

The Zacks Earnings ESP, ExplainedThe Zacks Earnings ESP is more formally known as the Expected Surprise Prediction, and it aims to grab the inside track on the latest analyst estimate revisions ahead of a company's report. The idea is relatively intuitive as a newer projection might be based on more complete information.

With this in mind, the Expected Surprise Prediction compares the Most Accurate Estimate (being the most recent) against the overall Zacks Consensus Estimate. The percentage difference provides the ESP figure. The system also utilizes our core Zacks Rank to provide a stronger system for identifying stocks that might beat their next quarterly earnings estimate and possibly see the stock price climb.

In fact, when we combined a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. Perhaps most importantly, using these parameters has helped produce 28.3% annual returns on average, according to our 10 year backtest.

Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.

Should You Consider Catalyst Pharmaceutical?The final step today is to look at a stock that meets our ESP qualifications. Catalyst Pharmaceutical (CPRX - Free Report) earns a #2 (Buy) seven days from its next quarterly earnings release on May 11, 2026, and its Most Accurate Estimate comes in at $0.69 a share.

By taking the percentage difference between the $0.69 Most Accurate Estimate and the $0.64 Zacks Consensus Estimate, Catalyst Pharmaceutical has an Earnings ESP of +7.81%. Investors should also know that CPRX is one of a large group of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

CPRX is just one of a large group of Medical stocks with a positive ESP figure. Idexx Laboratories (IDXX - Free Report) is another qualifying stock you may want to consider.

Slated to report earnings on May 5, 2026, Idexx Laboratories holds a #3 (Hold) ranking on the Zacks Rank, and its Most Accurate Estimate is $3.45 a share one day from its next quarterly update.

For Idexx Laboratories, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $3.42 is +0.77%.

CPRX and IDXX's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results.

First Quarter Results

The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group ("CAG") growth of 15% as reported and 12% organic.

First quarter earnings per diluted share (“EPS”) were $3.47, an increase of 17% as reported and 15% on a comparable basis. First quarter EPS included a $0.05 per share impact from a loss on an equity investment, $0.09 per share in tax benefits from share-based compensation, and $0.14 per share benefit from currency changes.

“Excellent commercial execution delivered exceptional first quarter results and positions IDEXX for continued strength through 2026,” said Jay Mazelsky, President and Chief Executive Officer. “IDEXX Cancer Dx™ platform momentum continues to build with the recent International launch and growing adoption in the U.S., and our IDEXX inVue Dx™ roll-out further advances our innovation-driven growth strategy. Initial customer response to the controlled launch of IDEXX inVue Dx FNA has been very encouraging and supports broadening access over the remainder of the year. As I transition from the CEO role, IDEXX remains well-positioned for continued success, and I look forward to continuing to work with Mike Erickson to drive long-term sustained growth in the business.”

First Quarter Performance Highlights

Companion Animal Group (“CAG”)

CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic, including 21% reported and 12% organic gains in International regions, and 11% reported and organic growth in the U.S., outpacing sector growth levels. U.S. growth was aided by a modest easing of clinical visit pressures and increased diagnostic frequency.

Additional U.S. companion animal practice key metrics are available in the Q1 2026 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.

Sustained commercial execution - including net customer gains, solid volume gains, benefits from IDEXX innovation, and expansion of the premium instrument installed base - drove double-digit CAG Diagnostics recurring revenue growth.

IDEXX VetLab™ consumables generated 20% reported and 15% organic revenue growth, supported by testing utilization gains, including increasing benefit from recent product launches, 12% growth in IDEXX's global premium instrument installed base, and net price gains. Reference laboratory diagnostic and consulting services generated 12% reported and 10% organic revenue growth, with benefits from higher testing volumes and net new customer gains. Rapid assay products revenues increased 1% as reported and were flat on an organic basis, driven by net price benefits with volume continuing to be impacted from the growing adoption of the Catalyst™ Pancreatic Lipase Test, which continues to shift some testing across modalities. CAG Diagnostics capital instrument revenues expanded 33% as reported and 28% on an organic basis, led by strong quarterly instrument placements, including benefits from 1,100 IDEXX inVue Dx placements.

Veterinary software, services and diagnostic imaging systems revenues grew 12% on a reported and 11% on an organic basis for the quarter, led by cloud-native software growth and continued installed base expansion, including record diagnostic imaging system installations.

Water

Water revenues grew 11% as reported and 7% organic for the quarter, reflecting solid organic growth in the U.S. and Latin America.

Livestock, Poultry and Dairy (“LPD”)

LPD revenues increased 14% as reported and 7% organic for the quarter, led by strong growth across core product categories.

Gross Profit and Operating Profit

Gross profit increased 16% as reported and 13% on a comparable basis. Gross margin of 63.4% increased 90 basis points as reported and comparable, supported by strong recurring revenue volume gains, operational productivity initiatives, and net price realization, which was offset by inflationary impacts and investments.

Operating margin was 31.8% for the quarter, higher than the prior year period by 10 basis points as reported and by 100 basis points on a comparable basis. Operating margin results reflect a 17% operating expense increase as reported and 11% growth on a comparable basis, including a $5 million loss on an equity investment in the current period and lapping a ~$9 million prior year benefit from a discrete expense accrual adjustment related to a concluded litigation matter. Operating expense growth was driven by investments in commercial capabilities, higher R&D spend related to advancing the Company's innovation agenda, further investment in the Veterinary Software and Services business, and higher employee benefit and incentive costs.

2026 Growth and Financial Performance Outlook

The Company is updating its full year revenue growth guidance range to $4,675 million - $4,760 million, or reported growth of 8.6% - 10.6%, an increase of $42 million at midpoint. This reflects a positive adjustment of ~1% at midpoint to full year estimates for reported revenue growth, reflecting strong CAG Diagnostics recurring revenue performance and outlook for modestly improving clinical visit trends. The Company is increasing its outlook for organic revenue growth to 7.7% - 9.7%, an increase of 0.7% at midpoint, reflecting the operational benefits highlighted above.

The Company increased its full year reported operating margin outlook to 32.1% - 32.5%, bringing the projected full year operating profit margin expansion to 50 - 90 basis points as reported and on a comparable basis. This outlook benefits from strong first quarter operating performance, while advancing strategic investment priorities.

The Company updated its EPS outlook range to $14.45 - $14.90, reflecting increased reported growth of 11% - 14% and 11% - 15% comparable growth. At midpoint this reflects benefits of $0.13 per share from operational performance and $0.05 from updated estimates for foreign exchange impacts, offset by $0.05 impact from a loss on an equity investment.

The following table provides the Company's updated outlook for annual key financial metrics in 2026 with a comparison to the prior outlook:

Amounts in millions except per share data and percentages

2026 Growth and Financial Performance Outlook

Updated

Prior

Revenue

$4,675

-

$4,760

$4,632

-

$4,720

Reported growth

8.6%

-

10.6%

7.6%

-

9.6%

Organic growth

7.7%

-

9.7%

7.0%

-

9.0%

CAG Diagnostics Recurring Revenue Growth

Reported growth

9.6%

-

11.6%

8.6%

-

10.6%

Organic growth

8.7%

-

10.7%

8.0%

-

10.0%

Operating Margin

32.1%

-

32.5%

32.0%

-

32.5%

Operating margin expansion

50 bps

-

90 bps

40 bps

-

90 bps

Comparable margin expansion

50 bps

-

90 bps

30 bps

-

80 bps

EPS

$14.45

-

$14.90

$14.29

-

$14.80

Reported growth

11%

-

14%

9%

-

13%

Comparable growth

11%

-

15%

10%

-

14%

Other Key Metrics

Net interest expense

~ $34

~ $34

Share-based compensation tax benefit

~ $15

~ $15

Share-based compensation tax rate benefit

~ 1.0%

~ 1.0%

Effective tax rate

~ 21.4%

~ 21.3%

Share-based compensation EPS impact

~ $0.19

~ $0.19

Reduction in average shares outstanding

1%

-

2%

1%

-

2%

Operating Cash Flow (% of Net Income)

105%

-

115%

105%

-

115%

Free Cash Flow (% of Net Income)

85%

-

95%

85%

-

95%

Capital Expenditures

~ $180

~ $180

The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2026.

Estimated Foreign Currency Exchange Rate Impacts

2026

Revenue growth rate impact

~0.9%

CAG Diagnostics recurring revenue growth rate impact

~0.9%

Operating margin growth impact

~ 30 bps

EPS impact

~ $0.27

EPS growth impact

~ 2%

Go-Forward Foreign Currency Exchange Rate Assumptions

2026

In U.S. dollars

euro

$1.16

British pound

$1.33

Canadian dollar

$0.72

Australian dollar

$0.70

Relative to the U.S. dollar

Japanese yen

¥160

Chinese renminbi

¥6.90

Brazilian real

R$5.15

Conference Call and Webcast Information

IDEXX Laboratories, Inc. will host a conference call today at 8:30 a.m. (ET) to discuss its first quarter 2026 results and management’s outlook. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (ET) via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 492760.

2026 Annual Meeting of Shareholders

IDEXX Laboratories, Inc. will hold its 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”) on Tuesday, May 12, 2026 at 10:00 a.m. (ET). The 2026 Annual Meeting will be a virtual meeting via a live audio webcast at www.virtualshareholdermeeting.com/IDXX2026. The online pre-meeting forum can be accessed before the 2026 Annual Meeting at www.proxyvote.com. At this online pre-meeting forum, you can submit questions in writing in advance of the 2026 Annual Meeting, vote, view the Rules of Conduct and Procedures relating to the 2026 Annual Meeting and access copies of the Company's proxy materials and annual report.

Shareholders as of the close of business on March 16, 2026 are entitled to attend the 2026 Annual Meeting, vote their shares electronically and submit questions before and during the live audio webcast. As part of the 2026 Annual Meeting, the Company will answer the questions submitted by our shareholders during a live Q&A session, as time permits. The Company will publish the answer to each question, including those which we are unable to address during the meeting due to time constraints during the 2026 Annual Meeting, on the Company’s Investor Relations website as soon as practicable after the meeting. An archived replay will be available at www.virtualshareholdermeeting.com/IDXX2026 after the conclusion of the 2026 Annual Meeting. Further information on the 2026 Annual Meeting can be found in the Company’s proxy materials.

About IDEXX Laboratories, Inc.

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.

Note Regarding Forward-Looking Statements

This earnings release and the statements to be made in the accompanying earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking statements are included above under "2026 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth (including instrument revenue growth in 2026) and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense; projected impact of tariffs; trends and other factors impacting the pet healthcare industry, including U.S. clinical visits; IDEXX inVue Dx analyzer placements; future IDEXX Cancer Dx testing panel addition; rollout of Fine Needle Aspiration to the IDEXX inVue Dx analyzer and future commercial and menu expansions; and future advancements in artificial intelligence. These statements are intended to provide management's expectations or forecasts of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs, and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of macroeconomic events, conditions, and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty, changes in U.S. and other countries’ tariff and trade policies, severe weather and other natural conditions, and supply chain challenges on our business, results of operations, liquidity, financial condition, and stock price, as well as the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in the corresponding sections of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Statement Regarding Non-GAAP Financial Measures

The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of the Company’s business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimate the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted first quarter 2026 results as follows: increased gross profit growth by 3.3%, no impact to gross margin expansion, increased operating expense growth by 2.0%, increased operating profit growth by 4.5%, increased operating profit margin growth by 40 basis points, and increased EPS growth by 4.6%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three months ended March 31, 2026 and refer to the 2026 Growth and Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2026 projections and estimates.

Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percent change in revenue, as compared to the same period for the prior year, net of the impact of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three months ended March 31, 2026. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Please refer to the 2026 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2026 organic revenue growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to have an immaterial impact on projected full year 2026 revenue growth and no impact on CAG Diagnostics recurring revenue growth. Projected second quarter 2026 organic revenue growth for the Company and CAG Diagnostics recurring revenue each reflects adjustment to projected second quarter 2026 organic revenue growth for the Company and CAG Diagnostics recurring revenue, as applicable, for a positive ~60 basis point impact from year-over-year foreign currency exchange rate changes at noted exchange rates; no impact to either of these projected growth measures is expected from acquisitions.

We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates by applying the difference between the weighted average exchange rates during the current year period and the comparable prior year period to foreign currency denominated revenues for the prior year period.

We also exclude from organic revenue growth the effect of certain business acquisitions and divestitures because the nature, size, and number of these transactions can vary dramatically from period to period, and because they either require or generate cash as an inherent consequence of the transaction, and therefore can also obscure underlying business and operating trends. We consider acquisitions to be a business when all three elements of inputs, processes, and outputs are present, consistent with ASU 2017-01, “Business Combinations: (Topic 805) Clarifying the Definition of a Business.” In a business combination, if substantially all the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, we do not consider these assets to be a business. A typical acquisition that we do not consider a business is a customer list asset acquisition, which does not have all elements necessary to operate a business, such as employees or infrastructure. We believe the efforts required to convert and retain these acquired customers are similar in nature to our existing customer base and therefore are included in organic revenue growth.

Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.

The reconciliation of these non-GAAP financial measures is as follows:

Three Months Ended

Year-over-Year

March 31,

March 31,

Change

Dollar amounts in thousands

2026

2025

Gross profit and growth (as reported)

$

722,739

$

623,379

16

%

Gross margin and margin gain

63.4

%

62.4

%

90 bps

Less: comparability adjustments

Change from currency

20,471

—

Comparable gross profit and growth

$

702,268

$

623,379

13

%

Comparable gross margin and margin gain

63.3

%

62.4

%

90 bps

Operating expenses and growth (as reported)

$

360,153

$

306,845

17

%

Less: comparability adjustments

Change from currency

6,270

—

Loss on equity investment

5,000

—

Now-concluded litigation matter

—

(8,600

)

Comparable operating expense and growth

$

348,883

$

315,445

11

%

Operating profit and growth (as reported)

$

362,586

$

316,534

15

%

Operating margin and margin gain

31.8

%

31.7

%

10 bps

Less: comparability adjustments

Change from currency

14,201

—

Loss on equity investment

(5,000

)

—

Now-concluded litigation matter

—

8,600

Comparable operating profit and growth

$

353,385

$

307,934

15

%

Comparable operating margin and margin gain

31.8

%

30.8

%

100 bps

Amounts presented may not recalculate due to rounding.

Projected 2026 comparable operating margin expansion outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) full year 2026 reported operating margin adjusted for $5 million unfavorable impact of loss on an equity investment; and (ii) adjustment to projected 2026 operating margin for a positive impact from year-over-year foreign currency exchange rate changes at noted exchange rates; and (iii) adjustment to 2025 operating margin for positive impact of the approximately $9 million discrete litigation expense accrual adjustment in the first quarter of 2025.

Projected second quarter 2026 comparable operating margin expansion reflects adjustment to projected second quarter 2026 operating margin expansion for a positive ~10 basis point impact from year-over-year foreign currency exchange rate changes at noted exchange rates.

These impacts described above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2026 and second quarter 2026 operating margin expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.

Comparable EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company’s business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.

The reconciliation of this non-GAAP financial measure is as follows:

Three Months Ended

Year-over-Year

March 31,

March 31,

Growth

2026

2025

Earnings per share (diluted) and growth

$

3.47

$

2.96

17

%

Less: comparability adjustments

Share-based compensation activity

0.09

0.01

Loss on equity investment

(0.05

)

—

Now-concluded litigation matter

—

0.08

Change from currency

0.14

—

Comparable EPS and growth

$

3.30

$

2.87

15

%

Amounts presented may not recalculate due to rounding.

Projected 2026 comparable EPS growth outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) adjustment to projected full year 2026 reported EPS for estimated positive year-over-year foreign currency exchange rate change impact of $0.27 at noted exchange rates; and (ii) adjustment to projected full year 2026 reported EPS for estimated positive impact of share-based compensation activity of ~$0.19; and (iii) adjustment to projected full year 2026 EPS of $0.05 for unfavorable impact of a loss on an equity investment; and (iv) adjustment to full year 2025 reported EPS for a positive $0.08 impact from the discrete litigation expense accrual adjustment in the first quarter of 2025; and (v) adjustment to full year 2025 reported EPS for positive impact of share-based compensation activity of $0.35.

These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2026 reported EPS growth) to comparable EPS growth for the Company.

Segment and Other Income from Operations - We report segment income from operations in our Segment Information table below. Segment income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and should be considered in addition to, and not as a replacement for, or superior measure to, income from operations. We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report the full amount of foreign currency transaction gains and losses in Other. We believe that reporting segment income from operations provides supplemental analysis to help investors further evaluate each reportable segment’s business performance by excluding foreign currency transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for assessing the results of each reportable segment’s operations. In addition, we believe that reporting segment income from operations provides information to investors regarding key metrics that are used by management, including our chief operating decision-maker, in evaluating the performance of each reportable segment.

The reconciliation of this non-GAAP financial measure is as follows for the three months ended March 31, 2026 and 2025:

Amounts in thousands

Three Months Ended March 31,

2026

2025

Income from Operations

Impact from Foreign Currency

Segment and Other Income from Operations

Income from Operations

Impact from Foreign Currency

Segment and Other Income from Operations

CAG

$

337,165

$

390

$

337,555

$

294,572

$

583

$

295,155

Water

23,643

26

23,669

20,774

43

20,817

LPD

1,262

28

1,290

80

45

125

Other

516

(444

)

72

1,108

(671

)

437

Total

$

362,586

$

—

$

362,586

$

316,534

$

—

$

316,534

Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company’s investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the three months ended March 31, 2026 and 2025. To estimate projected 2026 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $180 million. Free cash flow conversion, or the net income to free cash flow ratio, is a non-GAAP financial measure that is defined as free cash flow, with respect to a measurement period, divided by net income for the same period. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended March 31, 2026, we have deducted purchases of property and equipment of approximately $127 million from net cash provided from operating activities of approximately $1,210 million, divided by net income of approximately $1,095 million.

Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA, gross debt, and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Notes and Definitions

Discrete litigation expense accrual - During the first quarter of 2025, the Company reduced its previously established $89.0 million accrual related to a concluded litigation matter by approximately $9 million, which represented our best estimate at that time of the amount of the loss.

Concluded litigation matter - The Company was a defendant in a litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement, and the trial court ruled in favor of the plaintiff in 2020. Following appeals and in light of the appellate court's April 3, 2025 decision, on April 17, 2025, the Company paid the judgment of approximately $80 million, and the plaintiff executed a satisfaction and release of judgment, which was filed with the trial court on the same date, concluding this matter. For further information, see the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Operations

Amounts in thousands except per share data (Unaudited)

Three Months Ended

March 31,

March 31,

2026

2025

Revenue:

Revenue

$

1,140,820

$

998,427

Expenses and Income:

Cost of revenue

418,081

375,048

Gross profit

722,739

623,379

Sales and marketing

175,250

156,223

General and administrative

119,115

91,561

Research and development

65,788

59,061

Total operating expense

360,153

306,845

Income from operations

362,586

316,534

Interest expense, net

(7,144

)

(6,450

)

Income before provision for income taxes

355,442

310,084

Provision for income taxes

76,996

67,407

Net Income:

Net income attributable to stockholders

$

278,446

$

242,677

Earnings per share: Basic

$

3.50

$

2.98

Earnings per share: Diluted

$

3.47

$

2.96

Shares outstanding: Basic

79,648

81,319

Shares outstanding: Diluted

80,162

81,922

IDEXX Laboratories, Inc. and Subsidiaries

Selected Operating Information (Unaudited)

Three Months Ended

March 31,

March 31,

2026

2025

Operating Ratios

Gross profit

63.4

%

62.4

%

(as a percentage of revenue):

Sales, marketing, general and administrative expense

25.8

%

24.8

%

Research and development expense

5.8

%

5.9

%

Income from operations1

31.8

%

31.7

%

1Amounts presented may not recalculate due to rounding.

IDEXX Laboratories, Inc. and Subsidiaries

Segment and Other Information

Amounts in thousands (Unaudited)

Three Months Ended

March 31, 2026

Percent of Revenue

March 31, 2025

Percent of Revenue

Revenue:

CAG

$

1,054,052

$

919,836

Water

50,265

45,321

LPD

32,483

28,596

Other

4,020

4,674

Total

$

1,140,820

$

998,427

Gross Profit:

CAG

$

667,509

63.3

%

$

574,823

62.5

%

Water

36,537

72.7

%

32,073

70.8

%

LPD

16,910

52.1

%

14,365

50.2

%

Other

1,783

44.4

%

2,118

45.3

%

Total

$

722,739

63.4

%

$

623,379

62.4

%

Income from Operations:

CAG

$

337,555

32.0

%

$

295,155

32.1

%

Water

23,669

47.1

%

20,817

45.9

%

LPD

1,290

4.0

%

125

0.4

%

Other

72

1.8

%

437

9.3

%

Total

$

362,586

31.8

%

$

316,534

31.7

%

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)

Three Months Ended

March 31, 2026

March 31, 2025

Dollar Change

Reported Revenue Growth1

Percentage Change from
Currency

Percentage Change from Acquisitions

Organic Revenue Growth1

Net Revenue

CAG

$

1,054,052

$

919,836

$

134,216

14.6

%

3.0

%

—

11.6

%

United States

690,900

623,889

67,011

10.7

%

—

—

10.7

%

International

363,152

295,947

67,205

22.7

%

9.3

%

—

13.4

%

Water

$

50,265

$

45,321

$

4,944

10.9

%

3.8

%

—

7.1

%

United States

26,393

23,503

2,890

12.3

%

—

—

12.3

%

International

23,872

21,818

2,054

9.4

%

7.5

%

—

1.9

%

LPD

$

32,483

$

28,596

$

3,887

13.6

%

6.4

%

—

7.2

%

United States

6,384

5,788

596

10.3

%

—

—

10.3

%

International

26,099

22,808

3,291

14.4

%

7.9

%

—

6.5

%

Other

$

4,020

$

4,674

($

654

)

(14.0

%)

—

—

(14.0

%)

Total Company

$

1,140,820

$

998,427

$

142,393

14.3

%

3.1

%

—

11.2

%

United States

725,232

654,861

70,371

10.7

%

—

—

10.7

%

International

415,588

343,566

72,022

21.0

%

9.0

%

—

11.9

%

Three Months Ended

March 31, 2026

March 31, 2025

Dollar Change

Reported Revenue Growth1

Percentage Change from

Currency

Percentage Change from Acquisitions

Organic Revenue Growth1

Net CAG Revenue

CAG Diagnostics recurring revenue:

$

920,313

$

806,267

$

114,046

14.1

%

3.1

%

—

11.0

%

IDEXX VetLab consumables

412,582

344,779

67,803

19.7

%

4.2

%

—

15.4

%

Rapid assay products

84,938

84,034

904

1.1

%

1.2

%

—

(0.1

%)

Reference laboratory diagnostic and consulting services

386,179

344,406

41,773

12.1

%

2.5

%

—

9.7

%

CAG Diagnostics services and accessories

36,614

33,048

3,566

10.8

%

3.6

%

—

7.2

%

CAG Diagnostics capital – instruments

$

42,449

$

31,994

$

10,455

32.7

%

4.7

%

—

28.0

%

Veterinary software, services and diagnostic imaging systems:

$

91,290

$

81,575

$

9,715

11.9

%

1.0

%

—

10.9

%

Recurring revenue

73,536

65,793

7,743

11.8

%

1.1

%

—

10.7

%

Systems and hardware

17,754

15,782

1,972

12.5

%

0.5

%

—

12.0

%

Net CAG revenue

$

1,054,052

$

919,836

$

134,216

14.6

%

3.0

%

—

11.6

%

Three Months Ended

March 31, 2026

March 31, 2025

Dollar Change

Reported Revenue Growth1

Percentage Change from Currency

Percentage Change from Acquisitions

Organic Revenue Growth1

CAG Diagnostics recurring revenue:

$

920,313

$

806,267

$

114,046

14.1

%

3.1

%

—

11.0

%

United States

594,483

536,977

57,506

10.7

%

—

—

10.7

%

International

325,830

269,290

56,540

21.0

%

9.3

%

—

11.7

%

1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding. IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Balance Sheet

Amounts in thousands (Unaudited)

March 31, 2026

December 31, 2025

Assets:

Current Assets:

Cash and cash equivalents

$

200,528

$

180,070

Accounts receivable, net

603,544

552,378

Inventories

382,400

377,756

Other current assets

267,603

303,623

Total current assets

1,454,075

1,413,827

Property and equipment, net

740,382

747,380

Other long-term assets, net

1,191,040

1,189,552

Total assets

$

3,385,497

$

3,350,759

Liabilities and Stockholders'

Equity:

Current Liabilities:

Accounts payable

$

129,974

$

110,408

Accrued liabilities

453,552

530,147

Line of credit

530,000

398,000

Current portion of long-term debt

149,997

74,995

Deferred revenue

36,328

35,264

Total current liabilities

1,299,851

1,148,814

Long-term debt, net of current portion

299,854

374,842

Other long-term liabilities, net

229,689

221,720

Total long-term liabilities

529,543

596,562

Total stockholders' equity

1,556,103

1,605,383

Total liabilities and stockholders' equity

$

3,385,497

$

3,350,759

IDEXX Laboratories, Inc. and Subsidiaries

Selected Balance Sheet Information (Unaudited)

March 31,
2026

December 31,
2025

September 30,
2025

June 30,
2025

March 31,
2025

Selected Balance Sheet Information:

Days sales outstanding1

46.2

46.8

46.5

44.7

45.7

Inventory turns2

1.4

1.6

1.5

1.5

1.3

1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

2Inventory turns are calculated as the ratio of our inventory-related cost of revenue for the quarter multiplied by four, divided by the average inventory balances at the beginning and end of each quarter.

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Cash Flows

Amounts in thousands (Unaudited)

Three Months Ended

March 31, 2026

March 31, 2025

Operating:

Cash Flows from Operating Activities:

Net income

$

278,446

$

242,677

Non-cash adjustments to net income

77,550

55,972

Changes in assets and liabilities

(89,748

)

(60,687

)

Net cash provided by operating activities

266,248

237,962

Investing:

Cash Flows from Investing Activities:

Purchases of property and equipment

(31,984

)

(30,026

)

Acquisitions

(2,599

)

—

Proceeds from net investment hedges

1,039

416

Net cash used by investing activities

(33,544

)

(29,610

)

Financing:

Cash Flows from Financing Activities:

Borrowings under credit facility, net

132,000

69,500

Repurchases of common stock

(351,036

)

(400,890

)

Proceeds from exercises of stock options and employee stock purchase plans

18,161

7,193

Shares withheld for statutory tax withholding payments on restricted stock

(10,555

)

(6,124

)

Net cash used by financing activities

(211,430

)

(330,321

)

Net effect of changes in exchange rates on cash

(816

)

(2,327

)

Net increase (decrease) in cash and cash equivalents

20,458

(124,296

)

Cash and cash equivalents, beginning of period

180,070

288,266

Cash and cash equivalents, end of period

$

200,528

$

163,970

IDEXX Laboratories, Inc. and Subsidiaries

Free Cash Flow

Amounts in thousands (Unaudited)

Three Months Ended

March 31, 2026

March 31, 2025

Free Cash Flow:

Net cash provided by operating activities

$

266,248

$

237,962

Investing cash flows attributable to purchases of property and equipment

(31,984

)

(30,026

)

Free cash flow1

$

234,264

$

207,936

1See Statement Regarding Non-GAAP Financial Measures, above.

IDEXX Laboratories, Inc. and Subsidiaries

Common Stock Repurchases

Amounts in thousands except per share data (Unaudited)

Three Months Ended

March 31, 2026

March 31, 2025

Shares repurchased in the open market

588

931

Shares acquired through employee surrender for statutory tax withholding

17

14

Total shares repurchased

605

945

Cost of shares repurchased in the open market

$

360,833

$

409,215

Cost of shares for employee surrenders

10,555

6,124

Total cost of shares

$

371,388

$

415,339

Average cost per share – open market repurchases

$

613.87

$

439.64

Average cost per share – employee surrenders

$

629.35

$

444.52

Average cost per share – total

$

614.30

$

439.71

More News From IDEXX Laboratories, Inc.

This positive momentum comes as broader market indices, including the S&P 500 and Nasdaq, are also showing gains, with the S&P 500 up by 0.76% and the Nasdaq up by 0.90%.

Diagnostics Segment Drives Growth Across RegionsThe pet healthcare company reported first-quarter earnings of $3.47 per share, beating the consensus of $3.41.

Sales reached $1.14 billion, slightly above the consensus of $1.109 billion, equivalent to an organic growth of 11%.

A modest easing of clinical visit pressures and increased diagnostic frequency aided U.S. growth.

"Excellent commercial execution delivered exceptional first quarter results and positions IDEXX for continued strength through 2026," said Jay Mazelsky, President and CEO.

Conference Call HighlightsIDEXX Laboratories Inc's operating margin improved by 100 basis points, supported by gross margin expansion and strong recurring revenue growth.

The company highlighted strategic initiatives, including the launch of FNA and the expansion of its Cancer DX platform, with positive customer feedback and increased adoption.

Management emphasized the importance of diagnostics in veterinary care and the potential for AI to enhance innovation and diagnostics utilization.

The company is optimistic about its long-term growth prospects, supported by a strong innovation pipeline and expanding global presence.

Company Raises 2026 GuidanceIDEXX Laboratories raised its fiscal 2026 earnings from $14.29-$14.80 to $14.45-$14.90 compared to the consensus of $14.53.

The company increased its 2026 sales guidance from $4.63 billion-$4.72 billion to $4.675 billion-$4.76 billion compared to the consensus of $4.678 billion.

IDXX Technical Outlook: Key Support, Resistance And MomentumCurrently, Idexx Laboratories is trading at $564.00, which places it 2.6% below its 20-day simple moving average (SMA) of $572.90 and 5.1% below its 50-day SMA of $588.05.

The stock's relative strength index (RSI) is at 45.20, indicating a neutral momentum, suggesting that the stock is neither overbought nor oversold at this time.

Key Resistance: $594.50 — a nearby level where rebounds can stall. Key Support: $548.50 — a nearby level where buyers previously stepped in. IDXX Stock Price Activity: IDEXX Laboratories shares were up 3.35% at $582 during premarket trading on Tuesday, according to Benzinga Pro data.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Key Takeaways IDEXX posts Q1 EPS of $3.47, up 17.2%, beating estimates as revenues climbed 14% to $1.14B. IDEXX growth driven by CAG Diagnostics recurring revenues and software, imaging expansion. IDEXX raises 2026 outlook, guiding higher revenues and EPS on sustained growth momentum. IDEXX Laboratories, Inc. (IDXX - Free Report) posted first-quarter 2026 earnings per share (EPS) of $3.47, up 17.2% year over year. The figure surpassed the Zacks Consensus Estimate by 1.5%.

Comparable constant-currency EPS of $3.30 improved 15% year over year.

IDEXX’s RevenuesQuarterly revenues increased 14% year over year (up 11% organically) to $1.14 billion. The reported figure topped the Zacks Consensus Estimate by 2.1%.

Following the earnings announcement, IDXX shares gained 0.3% in the pre-market trading today.

IDEXX’s Q1 Revenue Analysis by SegmentsIDEXX derives revenues from four operating segments: CAG, Water, Livestock, Poultry andDairy (“LPD”), and Other.

CAG’s revenues rose 14.6% year over year on a reported basis and 11.6% on an organic basis to $1.05 billion.

CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic.  

Veterinary software, services and diagnostic imaging systems revenues grew 12% reportedly and 11% on an organic basis, led by cloud-native software growth and continued installed base expansion, including record diagnostic imaging system installations.

The Water segment’s revenues increased 10.9% year over year reportedly and 7.1% on an organic basis to $50.3 million.

For the first quarter, LPD revenues jumped 13.6% reportedly and 7.2% on an organic basis to $32.5 million.          

Revenues from the Other segment dropped 14% on a reported basis as well as organically to $4 million.

IDEXX’s Margin PerformanceGross profit rose 15.9% to $722.7 million. The gross margin expanded 92 basis points (bps) to 63.4% despite an 11.5% rise in the cost of revenues.

Sales and marketing expenses surged 12.2% to $175.3 million. G&A expenses rose 30.1% to $119.1 million. R&D expenses jumped 11.4% to $65.8 million. The operating profit in the reported quarter rose 14.5% year over year to $362.6 million. The operating margin in the quarter expanded 8 bps to 31.8%.

IDEXX’s Financial PositionIDEXX exited the first quarter of 2026 with cash and cash equivalents of $200.5 million compared with $180.1 million at the end of fourth-quarter 2025.

Cumulative net cash provided by operating activities was $266.3 million compared with $238 million in the prior-year period.

IDEXX Laboratories, Inc. Price, Consensus and EPS SurpriseIDEXX’s Upgraded 2026 GuidanceIDEXX upgraded an initial outlook for 2026, forecasting revenues in the range of $4,675-$4,760 million (up from $4,632-$4,720 million). The Zacks Consensus Estimate is currently pegged at $4.67 billion.

Full-year EPS is projected to be in the band of $14.45-$14.90 (up from the previous guidance of $14.29-$14.80), implying growth of 11-14% (up from 9-13%). The Zacks Consensus Estimate is currently pegged at $14.54.

Our View on IDEXXIDEXX exited the first quarter of 2026 with both revenues and earnings beating estimates. The performance was supported by consistently high levels of execution by IDEXX teams around the world. U.S. CAG Diagnostics’ recurring revenue growth was aided by increased diagnostic frequency, including modest easing of clinical visit pressures and increased diagnostic frequency. The expansion of both margins in the quarter is also encouraging.

The IDEXX Cancer Dx Platform continues to gain strong momentum, driven by its recent international expansion and increasing adoption across the United States. The rollout of IDEXX inVue Dx is further strengthening its innovation-led growth strategy. 

IDEXX’s Zacks Rank & Key PicksIDXX currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Phibro Animal Health (PAHC - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $1.28, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $826.4 million beat the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an earnings yield of 4.7% compared to the industry’s negative yield of 1.4%. The company’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.79%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a first-quarter 2026 adjusted EPS of $2.50, which exceeded the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion topped the Zacks Consensus Estimate by 6.2%.

ISRG has an earnings yield of 2.1% in contrast to the industry’s negative yield of 0.9%. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.

Phibro Animal Health, carrying a Zacks Rank #2 at present, posted a second-quarter fiscal 2026 adjusted EPS of 87 cents, which outpaced the Zacks Consensus Estimate by 27.01%. Revenues of $373.9 million outperformed the Zacks Consensus Estimate by 4.72%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 20.15%.

On May 11, 2026, IDEXX Laboratories Inc (IDXX) shares fell 5.0% to a current price of $532.00. This decline comes amid a challenging performance period for the

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a

Third menu expansion in four years broadens intestinal parasite detection in routine care

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Fecal Dx™ antigen testing platform with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than fecal flotation alone,1 Fecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care.

“This advancement reflects how we innovate at IDEXX, developing platforms that grow with our customers as care evolves.”

Share Since launching in 2012, more than 50 million Fecal Dx antigen tests have been run worldwide,2 reflecting strong clinical adoption over time. With each menu expansion, Fecal Dx has grown into a scalable diagnostic platform with increasing clinical scope and practice value.

“This advancement reflects how we innovate at IDEXX, developing platforms that grow with our customers as care evolves,” said Mike Erickson, President and CEO of IDEXX. “By broadening the insight available through Fecal Dx, we’re making fecal testing easier to incorporate into everyday decision-making, helping veterinary teams reach more pets with greater confidence.”

Taenia and Echinococcus species are recognized by the Companion Animal Parasite Council (CAPC) as clinically important parasites,3,4 with growing relevance for veterinarians worldwide. In particular, in areas where Echinococcus species is endemic, it can pose a significant zoonotic risk and remains a notable concern in parts of Europe, the United States and Canada. With this addition, Fecal Dx antigen testing now detects seven of the most clinically relevant intestinal parasite groups, including hookworm, roundworm, whipworm, flea tapeworm, taeniid tapeworm, Cystoisospora and Giardia (in select panels).

“The addition of taeniid tapeworm detection to IDEXX Fecal Dx makes this an even more complete intestinal parasite screen for cats and dogs,” said Michael Rose, DVM, Managing Owner, Monticello Animal Hospital.* “This allows veterinarians to institute medical treatment early, which helps protect pet health and reduce zoonotic risk to owners.”

Beginning in late June, Fecal Dx antigen testing panels and profiles for IDEXX Reference Laboratories customers in the United States and Canada will automatically include detection of taeniid tapeworm at no additional cost.

For more information, please visit the Fecal Dx antigen testing web page.

*Dr. Rose has received compensation for consulting services he has provided to IDEXX.

About IDEXX

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

Note Regarding Forward-Looking Statements

This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at sec.gov and via IDEXX’s website at idexx.com).

More News From IDEXX Laboratories, Inc.

Bullish or Bearish? Vetting Animal Health Care StocksIDEXX Laboratories NASDAQ: IDXX President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company’s innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics.

Erickson, who recently became CEO after roughly 14 years at the company, said IDEXX remains focused on a long-term strategy built around diagnostics, software and customer engagement. He described the company as “purpose-driven” and said its platform is intended to help veterinarians gain deeper clinical insights and improve practice productivity.

Get IDEXX Laboratories alerts:

“We’re really focused on innovation,” Erickson said. “I’ve never been more excited about our portfolio of innovations.”

Software and AI Remain Key Priorities Erickson said IDEXX sees significant opportunity in software and AI, both in its products and in internal operations. He pointed to inVue Dx and SediVue Dx as examples of AI already embedded in IDEXX diagnostic platforms.

With inVue Dx, Erickson said IDEXX has transformed manual, technique-sensitive cytology workflows by eliminating the need to make a slide in certain applications. The instrument uses optics and onboard AI to provide answers in about 10 minutes for areas such as cytology and blood morphology, he said.

He also said AI could help improve veterinary practice efficiency through tools such as ambient scribing and could support IDEXX’s own productivity. Erickson said some software teams at IDEXX are using AI to generate code, reducing work that previously took “weeks or months” to “days or weeks.”

Erickson said IDEXX may develop some AI-enabled capabilities internally while also partnering with third parties. He noted that the company has a connected software ecosystem with more than 100 third-party integrations.

inVue Dx Launch Described as One of IDEXX’s Most Successful Much of the discussion centered on inVue Dx, the company’s point-of-care diagnostic platform. Jonathan Block, managing director at Stifel, said IDEXX had previously discussed expectations for 5,500 placements in 2026 and noted that first-quarter placements were 1,100.

Erickson said inVue Dx has been “one of the most successful launches” in IDEXX history and said the company remains comfortable with its full-year forecast despite quarterly lumpiness. He said the initial applications in ear cytology and blood morphology address large categories of testing already occurring in veterinary hospitals.

The CEO said IDEXX continues to expand the platform’s menu through connected instruments. Since the company’s first-quarter call, he said IDEXX added additional red blood cell morphology capabilities, including spherocytes, schistocytes and keratocytes, after previously adding acanthocytes.

Erickson also said IDEXX is in a controlled launch for fine needle aspirate, or FNA, and expects to move to a broader launch later this year. He described FNA as a “platform within a platform” and said it addresses high-stakes cancer-related use cases, such as evaluating lumps and bumps in pets.

Block asked whether some practices might be waiting for the full FNA launch before adopting inVue Dx. Erickson said that could happen in some cases, but IDEXX has not seen it as a headwind to achieving its goals.

Erickson also said inVue Dx is already “comfortably” within the previously discussed $3,500 to $5,500 revenue-per-box range, even before the broader FNA launch. He said most practices with inVue Dx are using it for both ear cytology and blood morphology, and some customers want multiple instruments to handle volume.

Growth Outlook Tied to Multiple Drivers Asked about the company’s growth cadence for the remainder of the year, Erickson said IDEXX’s performance is not dependent on a single product. He pointed to double-digit first-quarter growth across point-of-care diagnostics and reference labs, including 15% growth in point-of-care consumables.

Erickson said innovation is helping IDEXX grow faster than the broader sector. He also said the company is seeing “green shoots” among dogs older than five, including in both wellness and non-wellness visits during the first quarter. The company has been facing headwinds in clinical visits, but Erickson said IDEXX modestly adjusted its full-year view from negative 2% to negative 1.5%.

John Ravis, vice president of investor relations, added that IDEXX is seeing benefits from net customer gains and adoption of new innovations. He said the company’s installed base grew 12% in the first quarter and that reference lab growth has accelerated across major modalities and geographies, including international markets.

Cancer Dx Seen as a Long-Term Development Opportunity Erickson also discussed Cancer Dx, IDEXX’s early cancer detection test that currently starts with lymphoma. Block said roughly 7,500 practices are ordering the test.

Erickson said IDEXX is pleased with demand and described the test as a breakthrough in a historically underdeveloped area of veterinary medicine. He said the test can detect lymphoma up to eight months before clinical signs and can help type the lymphoma to guide care.

The company has priced Cancer Dx at $15 when packaged with an IDEXX blood panel, which Erickson said supports broader access while also driving blood work at IDEXX reference labs. He said 70% of the Cancer Dx volume is being run together with blood work at IDEXX reference labs.

Erickson said about 20% of Cancer Dx volume is coming from practices that do not use IDEXX as their primary reference lab, which he said supports new customer growth. He also said IDEXX plans to add mast cell tumor later this year and expects to cover about one-third of major cancers after that addition. The company has said it expects to reach 50% coverage by 2028.

MilQ-ID Details Remain Limited Block also asked about MilQ-ID, a trademark he said Stifel had identified. Erickson declined to provide details on the product’s functionality or timing, saying IDEXX will discuss it when it is ready.

“What MilQ-ID will do, it will transform the category that it’s in, and it will be entirely complementary to what we have today in our IDEXX VetLab Suite,” Erickson said.

Asked whether IDEXX’s commercial organization can support multiple point-of-care analyzer innovations at the same time, Erickson said there is no capacity issue. He said the company has continued to invest in its commercial organization in the U.S. and internationally and plans to keep expanding that footprint.

Erickson closed by describing IDEXX’s innovation strategy as “multi-front,” spanning instruments, assays, software and AI. He said the company will continue to pursue integrated solutions across those areas.

About IDEXX Laboratories NASDAQ: IDXXIDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in IDEXX Laboratories Right Now?Before you consider IDEXX Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.

While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Idexx Laboratories (IDXX - Free Report) Headquartered in Westbrook, ME, IDEXX Laboratories, Inc. is a developer, manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

IDXX is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. IDXX has a Growth Style Score of B, forecasting year-over-year earnings growth of 12.2% for the current fiscal year.

Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.12 to $14.68 per share. IDXX also boasts an average earnings surprise of +6.1%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, IDXX should be on investors' short list.